Covid-19: Handling of Marketing Authorisations
Recommendation
Wednesday, 21 May 2025 10.00 - 16.00 h
How to use and prepare an MA with a CEP 2.0
Register now for ECA's GMP Newsletter
The processes and procedures relating to marketing authorisations are still strongly influenced by the corona pandemic. On the website of the HMA (Heads of Medicines Agencies) this has been reiterated and the available templates and information to facilitate and manage marketing authorisations and registration procedures have been consolidated and listed.
In addition to the continuously updated catalogue"QUESTIONS AND ANSWERS ON REGULATORY EXPECTATIONS FOR MEDICINAL PRODUCTS FOR HUMAN USE DURING THE COVID-19 PANDEMIC", the "Template for submission of an application for a Covid-19 exeptional change management process (ECMP)" and the "Template for Step 3 Notification of implementation" are available here.
The overview of the information provided and application templates can be found on the website of the HMA (Heads of Medicines Agencies) in the section CMDh.
Related GMP News
16.04.2025EMA: Revised IRIS Documents
09.04.2025Centralised Procedures: Q&As Updated
12.03.2025CMDh/HMA: Guidance Documents on Variation Notifications Updated
11.03.2025EMA: Renewal of Q&A Document for "Centralized Procedures"
11.03.2025Centralised Procedures: Q&A Documents also Updated for Biosimilars
29.01.2025CMDh/HMA: Updated Guidance Documents on Variation Notifications